Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.

Molecular Cytogenetics Group, Human Cancer Genetics programme, Centro Nacional Investigaciones Oncologicas, Centro de Investigaciones de Enfermedades Raras, Madrid, Spain.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 9.38). 01/2012; 26(6):1329-37. DOI: 10.1038/leu.2011.376
Source: PubMed

ABSTRACT The AML1-ETO fusion protein, which is present in 10-15% of cases of acute myeloid leukemia, is known to repress myeloid differentiation genes through DNA binding and recruitment of chromatin-modifying proteins and transcription factors in target genes. ChIP-chip analysis of human hematopoietic stem/progenitor cells transduced with the AML1-ETO fusion gene enabled us to identify 1168 AML1-ETO target genes, 103 of which were co-occupied by histone deacetylase 1 (HDAC1) and had lost the hyperacetylation mark at histone H4, and 264 showed a K9 trimethylation at histone H3. Enrichment of genes involved in hematopoietic differentiation and in specific signaling pathways was observed in the presence of these epigenetic modifications associated with an 'inactive' chromatin status. Furthermore, AML1-ETO target genes had a significant correlation between the chromatin marks studied and transcriptional silencing. Interestingly, AML1 binding sites were absent on a large number of selected AML1-ETO promoters and an Sp1 binding site was found in over 50% of them. Reversible silencing induced by the fusion protein in the presence of AML1 and/or Sp1 transcription factor binding site was confirmed. Therefore, this study provides a global analysis of AML1-ETO functional chromatin modifications and identifies the important role of Sp1 in the DNA binding pattern of AML1-ETO, suggesting a role for Sp1-targeted therapy in this leukemia subtype.


Available from: James C Mulloy, Jun 10, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein/protein interactions (PPIs) are essential for all biological processes. Their role as central control switches and checkpoints in signaling and regulation makes their dysfunction an eminent cause of cancer and other diseases. Thus, a target-oriented intervention with PPIs, in particular by small molecules suitable for a pharmacological therapy, is the object of intense research. In the recent years, this research of PPIs yielded a number of low-molecular protein/protein interaction modulators (PPIMs). However, only a few PPIMs were identified by rational or structure-based considerations. The reason is that it is difficult to directly re-use well-established computational methods to identify ligands of conventional targets, such as enzymes, receptors, or transporters. Conventional targets naturally bind small molecules via pronounced complementary binding pockets. In contrast, many protein/protein interfaces (PPIfaces) are large and lack pronounced pockets. Thus, it is hard to find small molecules with an affinity and specificity that is adequate to displace one of the binding proteins. Nevertheless, the widespread discovery of (drug-like) PPIMs shows: these challenges can be overcome, and PPIs are not undruggable in general. The goal of this thesis was to develop a computational strategy for the rational identification of PPIMs, notably of NHR2 inhibitors, starting only with a protein/protein complex structure (PPI structure). This task subdivides into the four core themes of this thesis. First, I reviewed the knowledge about PPIs, PPIMs, the determinants of their interactions as well as computational methods for the identification of druggable sites and PPIMs. Second, I implemented a strategy that uses a PPI-structure based prediction of hot spots and transient pockets to guide a structure-based virtual screening. As a validation, I retrieved known PPIMs that bind to the PPIface of interleukin-2 from a large set of non-binders. Third, I analyzed the potential of teroxazoles as a new class of hydrophilic α-helix mimetics. These present side chains similar to α-helices and mimic a sequence pattern that has not yet been considered. Fourth, I identified the first micromolar inhibitors of the NHR2-mediated tetramerization of RUNX1-ETO (RE) from dimers, a prerequisite for the onset and maintenance of RE-dependent acute myeloid leukemia (RE-AML). Predicted tetramerization hot spots close to the largest pocket in the PPIface guided the computational identification of drug-like PPIMs. These PPIMs mimic NHR2 hot spots, aim at the PPIface, and inhibit dimer association as well as the proliferation of RE-dependent cells. These PPIMs are valuable as probes and tools to study the effects of NHR2 tetramerization and are an important step towards a personalized therapy of RE-AML. Most importantly, however, the presented strategy can well be the first step in any comparable structure-based endeavor to identify or design PPIMs, even in cases where only a PPI structure with a rather flat PPIface is known.
    10/2014, Degree: Dr. rer. nat. (PhD), Supervisor: Holger Gohlke
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A broad range of human leukemias carries RUNX1 and MLL genetic alterations. Despite such widespread involvements, the relationship between RUNX1 and MLL has never been appreciated. Recently, we showed that RUNX1 physically and functionally interacts with MLL, thereby regulating epigenetic status of critical cis-regulatory elements for hematopoietic genes. This newly unveiled interaction between two most prevalent leukemia genes has solved a long-standing conundrum: leukemia-associated RUNX1 N-terminal point mutants which exhibit no obvious functional abnormalities in classical assays for the assessment of transcriptional activities. These mutants turned out to be defective in MLL interaction and subsequent epigenetic modifications which can be examined by the histone modification status of cis-regulatory elements in the target genes. RUNX1/MLL binding confirms the importance of RUNX1 function as an epigenetic regulator. Recent studies employing next generation sequencing on human hematological malignancies identified a plethora of mutations in epigenetic regulator genes. These new findings would enhance our understanding on the mechanistic basis for leukemia development and may provide a novel direction for therapeutic applications. This review summarizes the current knowledge about epigenetic regulation of normal and malignant hematopoiesis by RUNX1 and MLL.Leukemia accepted article preview online, 2 July 2013; doi:10.1038/leu.2013.200.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 07/2013; DOI:10.1038/leu.2013.200 · 9.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transcriptional regulation involves complex and interdependent interactions of noncoding and coding regions of the genome with proteins that interact and modify them. Genetic variation/mutation in coding and noncoding regions of the genome can drive aberrant transcription and disease. In spite of accounting for nearly 98% of the genome comparatively little is known about the contribution of noncoding DNA elements to disease. Genome-wide association studies of complex human diseases including cancer have revealed enrichment for variants in the noncoding genome. A striking finding of recent cancer genome re-sequencing efforts has been the previously underappreciated frequency of mutations in epigenetic modifiers across a wide range of cancer types. Taken together these results point to the importance of dysregulation in transcriptional regulatory control in genesis of cancer. Powered by recent technological advancements in functional genomic profiling, exploration of normal and transformed regulatory networks will provide novel insight into the initiation and progression of cancer and open new windows to future prognostic and diagnostic tools. For further resources related to this article, please visit the WIREs website. Conflict of interest: The author has declared no conflicts of interest for this article.
    Wiley Interdisciplinary Reviews Systems Biology and Medicine 01/2014; 6(1). DOI:10.1002/wsbm.1250 · 3.01 Impact Factor